mardi 10 mars 2020

Onco Acu du 10 mars 2020


4.1 DÉP., DIAG. & PRONO. - PROSTATE



Urine test could reduce unnecessary prostate cancer biopsies [EurekAlert!]











4.10 DÉP., DIAG. & PRONO. - POUMON



Combining smoke cessation programs with screening for lung cancer can reduce mortality [University of Michigan]










4.12 BIOPSIES LIQUIDES



Prostate cancer 'fingerprint' detected in blood sample [EurekAlert!]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Cancerous tumors, surrounding cells illuminated by new imaging agent [WUSTL]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Integrated Genomic Analysis Highlights Potential Strategy for Overcoming Some ALL Resistance [Genome Web]











4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Assessment of Treatment Cost-effectiveness Using a Colorectal Cancer Mutation Profile [JAMA Network Open]











4.9 DÉP., DIAG. & PRONO. - SEIN



Breast cancer ‘breakthrough’ could end unnecessary biopsies [Pharma Times]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Could Leukemia Be Stopped Before It Starts? Researchers Aim to Find Out [Dana-Farber Cancer Institute]










St. Jude finds cancer drug resistance genes and possibly how to limit their effects [St. Jude Chlidren's Research Hospital]











5.10 TRAITEMENTS - ESSAIS



Inclusion of Older Adults in Cancer Clinical Trials [FDA]










FDA Encourages Inclusion of Older Patients in Cancer Trials [RAPS]











Study Uncovers Bias and Stereotyping When Recruiting Patients for Clinical Trials [Wiley]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Withdrawal of Application to Change the EU Marketing Authorisation for Nivolumab and Ipilimumab [ESMO]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Vasella helps Numab to CHF22M round ahead of cancer trial start [Fierce Biotech]











5.2 PHARMA



BMS' Empliciti misses shot at new myeloma market with phase 3 failure [Fierce Pharma]











Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy [EndPoints]










Bristol-Myers' multiple myeloma combo therapy fails study [Reuters]











Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma [BMS]











5.2.6 PHARMA - BIOTECH



That was fast: 3 months after uncloaking, Zentalis guns for IPO [Fierce Biotech]











Unum racks up yet another FDA hold as it twists its way through a restructuring, looking for a fresh start with a preclinical drug [EndPoints]











5.3 TRAITEMENTS - FDA, EMA,...



Addressing the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU [EMA]











6. LUTTE CONTRE LES CANCERS



MD Anderson implements additional restrictions due to 2019 novel coronavirus disease (COVID-19) [MD Anderson Cancer Center]











6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



Publishers roll out alternative routes to open access [Science]











6.7.3 DMP



New Trump rules aim to fuel sharing of patient health records by smartphone [STAT]











6.8 COMMUNICATION



Improving Physician Communication About Treatment Decisions [JAMA]